Feeds › Planned insider sales
Planned insider sales
Notices (SEC Form 144) that executives and other insiders file before selling shares, and whether a sale was reported afterwards.
About this data
- What it is
- Before an executive, director or large owner sells restricted or control shares, they file a short notice with the SEC, called Form 144, saying how many shares they plan to sell, through which broker and roughly when. This feed lists those notices, and for each one shows whether a sale was reported afterwards on a Form 4 and how many days later.
- Who files it
- The person selling, or their broker, on the day the sale is placed. Electronic notices start in April 2023.
- How current
- We collect new notices throughout the day on SEC business days.
- Terms
- Form 144The notice an insider or other affiliate of a company files with the SEC before selling restricted or control shares, so the shares can be sold under Rule 144. The notice says how many shares, through which broker, and roughly when.10b5-1 planA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan.
- Worth knowing
- A notice is a plan, not a sale: the person may sell fewer shares, later, or not at all. The value is the one the filer typed, at a price they chose, not what the shares sell for. Many sales are routine, made to diversify or pay taxes, or under a 10b5-1 plan set up months earlier. A blank in the last column does not mean no sale: the person may not have to file a Form 4 (an ordinary affiliate does not), the sale may be recent, or the Form 4 may name a different spelling of the person. We match by the filer's number first and by name second. Information, not investment advice.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Form 144 notices per day, last 30 days
All notices Notices that give a 10b5-1 plan
By the day each notice was filed. A notice is a plan to sell, not a sale.
Latest notices of planned insider sales
Showing: ticker XFOR
| Filed | Insider | Company | Shares to sellA notice is a plan, not a sale. The person may sell fewer shares, sell later, or not sell at all, and the number of shares is what they expect to sell on the day they file. | ValueThe aggregate market value the filer typed on the notice: the shares times a price the filer chose. It is not what the shares will sell for. | PlanA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan. | Expected sale | Sale reportedInsiders who are officers, directors or hold more than 10% report their sales on a Form 4, within two business days. We look for the first Form 4 with an open-market sale by the same person in the same company within 90 days of the notice, and show how many days after the notice it was filed. A blank means we found none: the person may not have sold, may not have to file a Form 4, or the Form 4 may be one we do not have. | Notice |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | David Kirske Officer | XFOR X4 Pharmaceuticals, Inc. | 11,767 | $33.7K | — | Oct 1, 2026 | — | Form 144 ↗ |
| Aug 13, 2026 | John Volpone Officer | XFOR X4 Pharmaceuticals, Inc. | 24,576 | $111.9K | — | Aug 12, 2026 | Form 4 ↗ same day · 24,576 shares | Form 144 ↗ |
| Aug 13, 2026 | Adam Craig Executive Chaiman | XFOR X4 Pharmaceuticals, Inc. | 47,436 | $216.1K | — | Aug 12, 2026 | Form 4 ↗ same day · 47,436 shares | Form 144 ↗ |
| May 12, 2026 | David Kirske Officer | XFOR X4 Pharmaceuticals, Inc. | 16,961 | $72.8K | — | May 12, 2026 | Form 4 ↗ 1 day later · 16,961 shares | Form 144 ↗ |
| Jan 24, 2025 | Paula Ragan Officer | XFOR X4 Pharmaceuticals, Inc. | 76,473 | $39.8K | 10b5-1 | Jan 24, 2025 | Form 4 ↗ 3 days later · 76,473 shares | Form 144 ↗ |
| Jan 24, 2025 | Adam S. Mostafa Officer | XFOR X4 Pharmaceuticals, Inc. | 74,773 | $38.9K | 10b5-1 | Oct 7, 2024 | Form 4 ↗ 3 days later · 74,773 shares | Form 144 ↗ |
| Jan 24, 2025 | Mary DiBiase Officer | XFOR X4 Pharmaceuticals, Inc. | 22,258 | $11.6K | 10b5-1 | Jan 24, 2025 | Form 4 ↗ 3 days later · 22,258 shares | Form 144 ↗ |
| Jan 24, 2025 | Arthur Taveras Officer | XFOR X4 Pharmaceuticals, Inc. | 24,828 | $12.9K | 10b5-1 | Jan 24, 2025 | — | Form 144 ↗ |
| Jan 24, 2025 | Arbet-Engels Christophe Officer | XFOR X4 Pharmaceuticals, Inc. | 11,624 | $6,044 | 10b5-1 | Jan 24, 2025 | Form 4 ↗ 3 days later · 11,624 shares | Form 144 ↗ |
| Jan 24, 2025 | Mark Baldry Officer | XFOR X4 Pharmaceuticals, Inc. | 29,159 | $15.2K | 10b5-1 | Jan 24, 2025 | Form 4 ↗ 3 days later · 29,159 shares | Form 144 ↗ |
| Nov 15, 2024 | Paula Ragan Officer | XFOR X4 Pharmaceuticals, Inc. | 31,897 | $13.1K | 10b5-1 | Nov 15, 2024 | Form 4 ↗ 4 days later · 31,897 shares | Form 144 ↗ |
| Oct 15, 2024 | Paula Ragan Officer | XFOR X4 Pharmaceuticals, Inc. | 31,897 | $17.9K | 10b5-1 | Oct 15, 2024 | Form 4 ↗ 1 day later · 31,897 shares | Form 144 ↗ |
| Oct 7, 2024 | Mary DiBiase Officer | XFOR X4 Pharmaceuticals, Inc. | 67,695 | $43.1K | 10b5-1 | Oct 7, 2024 | Form 4 ↗ 1 day later · 67,695 shares | Form 144 ↗ |
| Oct 7, 2024 | Adam S. Mostafa Officer | XFOR X4 Pharmaceuticals, Inc. | 230,645 | $146.8K | 10b5-1 | Oct 7, 2024 | Form 4 ↗ 1 day later · 230,645 shares | Form 144 ↗ |
| Oct 7, 2024 | Paula Ragan Officer | XFOR X4 Pharmaceuticals, Inc. | 239,436 | $152.4K | 10b5-1 | Oct 7, 2024 | Form 4 ↗ 1 day later · 239,436 shares | Form 144 ↗ |
| Oct 7, 2024 | Mark Baldry Officer | XFOR X4 Pharmaceuticals, Inc. | 11,127 | $7,083 | 10b5-1 | Oct 7, 2024 | Form 4 ↗ 1 day later · 11,127 shares | Form 144 ↗ |
| Oct 7, 2024 | Arthur Taveras Officer | XFOR X4 Pharmaceuticals, Inc. | 76,920 | $49.0K | 10b5-1 | Oct 7, 2024 | Form 4 ↗ 1 day later · 76,920 shares | Form 144 ↗ |
| Sep 9, 2024 | Mary DiBiase Officer | XFOR X4 Pharmaceuticals, Inc. | 2,642 | $1,728 | 10b5-1 | Sep 9, 2024 | Form 4 ↗ 29 days later · 67,695 shares | Form 144 ↗ |
| Mar 11, 2024 | Arthur Taveras Officer | XFOR X4 Pharmaceuticals, Inc. | 14,235 | $12.8K | 10b5-1 | Mar 11, 2024 | — | Form 144 ↗ |
| Mar 11, 2024 | Adam S. Mostafa Officer | XFOR X4 Pharmaceuticals, Inc. | 52,500 | $47.3K | 10b5-1 | Mar 11, 2024 | — | Form 144 ↗ |
| Mar 11, 2024 | Mary DiBiase Officer | XFOR X4 Pharmaceuticals, Inc. | 15,409 | $13.9K | 10b5-1 | Mar 11, 2024 | — | Form 144 ↗ |
| Mar 11, 2024 | Paula Ragan Officer | XFOR X4 Pharmaceuticals, Inc. | 49,678 | $44.7K | 10b5-1 | Mar 11, 2024 | — | Form 144 ↗ |
| Feb 12, 2024 | Arthur Taveras Officer | XFOR X4 Pharmaceuticals, Inc. | 787 | $763 | 10b5-1 | Feb 12, 2024 | — | Form 144 ↗ |
| Feb 12, 2024 | Adam S. Mostafa Officer | XFOR X4 Pharmaceuticals, Inc. | 27,721 | $26.9K | 10b5-1 | Feb 12, 2024 | — | Form 144 ↗ |
| Feb 12, 2024 | Mary DiBiase Officer | XFOR X4 Pharmaceuticals, Inc. | 3,683 | $3,573 | 10b5-1 | Feb 12, 2024 | — | Form 144 ↗ |
| Feb 12, 2024 | Paula Ragan Officer | XFOR X4 Pharmaceuticals, Inc. | 21,695 | $21.0K | 10b5-1 | Feb 12, 2024 | — | Form 144 ↗ |
| Nov 3, 2023 | Paula Ragan Officer | XFOR X4 Pharmaceuticals, Inc. | 39,906 | $32.1K | 10b5-1 | Nov 3, 2023 | — | Form 144 ↗ |
| Nov 1, 2023 | Paula Ragan Officer | XFOR X4 Pharmaceuticals, Inc. | 199,531 | $157.8K | 10b5-1 | Nov 1, 2023 | — | Form 144 ↗ |
| Nov 1, 2023 | Mary DiBiase Officer | XFOR X4 Pharmaceuticals, Inc. | 67,695 | $53.6K | 10b5-1 | Nov 1, 2023 | — | Form 144 ↗ |
| Nov 1, 2023 | Arthur Taveras Affiliate | XFOR X4 Pharmaceuticals, Inc. | 67,695 | $53.6K | 10b5-1 | Nov 1, 2023 | — | Form 144 ↗ |
| Nov 1, 2023 | Mark Baldry Officer | XFOR X4 Pharmaceuticals, Inc. | 10,257 | $8,144 | 10b5-1 | Nov 1, 2023 | — | Form 144 ↗ |
| Nov 1, 2023 | Adam S. Mostafa Officer | XFOR X4 Pharmaceuticals, Inc. | 230,645 | $182.5K | 10b5-1 | Nov 1, 2023 | — | Form 144 ↗ |
| Sep 8, 2023 | Mary DiBiase Officer | XFOR X4 Pharmaceuticals, Inc. | 2,642 | $3,276 | 10b5-1 | Sep 8, 2023 | — | Form 144 ↗ |
| Jun 30, 2023 | Mary DiBiase Officer | XFOR X4 Pharmaceuticals, Inc. | 464 | $878 | 10b5-1 | Jun 30, 2023 | — | Form 144 ↗ |
| Jun 30, 2023 | Adam S. Mostafa Officer | XFOR X4 Pharmaceuticals, Inc. | 2,641 | $5,000 | 10b5-1 | Jun 30, 2023 | — | Form 144 ↗ |
| Jun 23, 2023 | Mary DiBiase Officer | XFOR X4 Pharmaceuticals, Inc. | 857 | $1,652 | 10b5-1 | Jun 23, 2023 | — | Form 144 ↗ |
| Jun 23, 2023 | Paula Ragan Officer | XFOR X4 Pharmaceuticals, Inc. | 6,724 | $12.9K | 10b5-1 | Jun 23, 2023 | — | Form 144 ↗ |
| Jun 23, 2023 | Adam S. Mostafa Officer | XFOR X4 Pharmaceuticals, Inc. | 5,417 | $10.6K | 10b5-1 | Jun 23, 2023 | — | Form 144 ↗ |
| Jun 15, 2023 | Paula Ragan Officer, President and CEO | XFOR X4 Pharmaceuticals, Inc. | 6,724 | $15.0K | 10b5-1 | Jun 15, 2023 | — | Form 144 ↗ |
| Jun 15, 2023 | Mary DiBiase Officer | XFOR X4 Pharmaceuticals, Inc. | 857 | $1,911 | 10b5-1 | Jun 15, 2023 | — | Form 144 ↗ |
| Jun 15, 2023 | Adam S. Mostafa Officer | XFOR X4 Pharmaceuticals, Inc. | 5,417 | $12.1K | 10b5-1 | Jun 15, 2023 | — | Form 144 ↗ |
| May 31, 2023 | Paula Ragan Officer, President and CEO | XFOR X4 Pharmaceuticals, Inc. | 6,292 | $12.3K | 10b5-1 | May 31, 2023 | — | Form 144 ↗ |
42 items, most recent first (up to 50). Every row links to the notice on the SEC's site, and to the Form 4 when we found one. Updated Nov 15, 2026, 5:52 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances